Nurix (NRIX) Soars 18.7% on Encouraging Blood Cancer Treatment Trial

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Nurix Therapeutics Inc. (NASDAQ:NRIX) is one of the best performers on Monday.

Nurix Therapeutics extended its winning streak to a fourth straight day on Monday, jumping 18.68 percent to finish at $21.47 apiece as investors took heart from the promising results of its clinical trial for bexobrutideg in patients with a rare blood cancer called Waldenström macroglobulinemia.

In an updated report, Nurix Therapeutics Inc. (NASDAQ:NRIX) said that it tested 200mg to 600mg of the therapy candidate on 31 patients aged 49 to 88 years, who have already tested more than several other treatments.

The study showed that bexobrutideg showed an objective response rate of 75 percent, including very good partial responses in three patients, partial responses in 14 patients, and minor responses in four patients. Six patients also had a best response of stable disease.

As of the September 19, 2025, data cut, 15 patients continued on treatment for more than six months, while six patients remained on treatment for more than one year.

Notably, the drug candidate was well tolerated, with adverse events only reported at low grade, with the most common being neutropenia, petechiae, diarrhea, anemia, purpura/contusion, and thrombocytopenia.

“These clinical data and recent data highlighting the unique properties of our potent and highly selective BTK degrader contribute to a growing body of evidence that supports bexobrutideg’s potential to be the best-in-class and an important new therapeutic option for patients,” said Nurix Therapeutics Inc. (NASDAQ:NRIX) President and CEO Arthur Sands.

“We believe bexobrutideg is an innovative therapy with the potential to transform care in CLL (chronic lymphocytic leukemia), WM, and additional NHL (non-Hodgkin lymphoma) indications, while supporting long-term value creation as its development expands into inflammatory and autoimmune settings,” he added.

While we acknowledge the potential of NRIX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.